147 related articles for article (PubMed ID: 38009230)
1. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
Yang T; Zhou Y; Cui Y
Expert Opin Drug Saf; 2023 Nov; ():1-6. PubMed ID: 38009230
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.
Mohammad H; Borja-Hart N
J Pharm Technol; 2018 Aug; 34(4):144-148. PubMed ID: 34860970
[No Abstract] [Full Text] [Related]
3. A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use.
Shen J; Yang J; Zhao B
Diabetes Ther; 2019 Jun; 10(3):1043-1050. PubMed ID: 30953300
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials.
Bhanushali KB; Asnani HK; Nair A; Ganatra S; Dani SS
Curr Probl Cardiol; 2024 May; 49(9):102664. PubMed ID: 38789017
[TBL] [Abstract][Full Text] [Related]
5. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
6. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
Engelhardt K; Ferguson M; Rosselli JL
Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
8. Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study.
Amos TB; Montejano L; Juneau P; Bolge SC
J Med Econ; 2017 Mar; 20(3):303-313. PubMed ID: 27826987
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
10. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
[TBL] [Abstract][Full Text] [Related]
11. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
14. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
15. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
Nair HP; Kulkarni AR; Eswaran M; Subeesh V
Arab J Gastroenterol; 2023 Feb; 24(1):1-4. PubMed ID: 36725376
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
17. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
Pan Y; Wang Y; Zheng Y; Chen J; Li J
Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis.
Raghuvanshi S; Rahman MA; Posa MK; Kumar A
Curr Drug Saf; 2023 Nov; ():. PubMed ID: 37990902
[TBL] [Abstract][Full Text] [Related]
19. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis.
Gravel CA; Krewski D; Mattison DR; Momoli F; Douros A
Br J Clin Pharmacol; 2023 Aug; 89(8):2430-2445. PubMed ID: 36912450
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases.
Tran BA; Updike WH; Bullers K; Serag-Bolos E
Clin Diabetes; 2022 Jan; 40(1):78-86. PubMed ID: 35221476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
